CAMBRIDGE, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced its participation in upcoming investor conferences. Presentation details with President and Chief Executive Officer, Mark Velleca, M.D., Ph.D., are as follows: 24th Annual Needham Virtual Healthcare Conference presentation at 3:00pm ET on Monday, April 7, 2025Stifel 2025 Virtual Targeted Oncology Forum fireside chat at 1:00pm ET on Tuesday, April 8, 2025 Webcasts will be available at the start of the presentations on the investor rel

The partnership underscores Servier's commitment to developing targeted therapies that address unmet medical needs in oncologyServier will develop and commercialize BDTX-4933, a Phase 1 asset with best-in-class potential targeting both RAS mutations and RAF alterations, in solid tumors, including non-small cell lung cancerBlack Diamond will receive an upfront payment of $70 million and up to $710 million in development and commercial sales milestone payments plus royalties SURESNES, France and CAMBRIDGE, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- Servier, an independent global pharmaceutical group governed by a non-profit foundation, and Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a

Clinical data on track for Q2 2025 in Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLCExpansion of investigator sponsored "window of opportunity" trial into newly diagnosed glioblastoma patients with EGFR aberrations expected in Q1 2025Cash, cash equivalents, and investments of $98.6 million as of December 31, 2024, expected to be sufficient to fund operations into Q4 2026 CAMBRIDGE, Mass., March 06, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today reported financial results for the fourth quarter an

New board reflects company's added focus on oncology & autoimmune diseases SARASOTA, Fla. and MIAMI, Feb. 19, 2025 (GLOBE NEWSWIRE) -- NAYA Biosciences ("NAYA") (NASDAQ:NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and women's health, today announced that its board of directors has nominated five new candidates with extensive experience in in the biotechnology industry to be approved at the company shareholder meeting scheduled for March 10th, 2025. Laurent Audoly, PhD is the cofounder and CEO of PriveBio, a precision medicine company, and a professor and strategic advisor at the Institute for Experient

Announced encouraging initial Phase 2 data of BDTX-1535 in patients with recurrent EGFRm NSCLC with a broad spectrum of classical, non-classical, and C797S resistance mutations in September 2024 Presented real-world treatment practices and patient outcomes in newly diagnosed NSCLC patients with non-classical EGFR mutations at the 2024 ESMO Congress Clinical updates of BDTX-1535 in EGFRm NSCLC and regulatory feedback expected in Q1 2025Cash, cash equivalents, and investments of $112.7 million as of September 30, 2024; expected to be sufficient to fund operations into Q2 of 2026 CAMBRIDGE, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a clinical-st

CAMBRIDGE, Mass., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced its participation in upcoming investor conferences. Presentation details with President and Chief Executive Officer, Mark Velleca, M.D., Ph.D., are as follows: Stifel Healthcare Conference fireside chat at 4:10pm ET on Tuesday, November 19, 2024Piper Sandler 36th Annual Healthcare Conference fireside chat at 3:00pm ET on Wednesday, December 4, 2024 Webcasts will be available at the start of the presentations on the investor relations section

Company advancing BDTX-1535 in EGFRm NSCLC towards key inflection points in Q1 2025 Will deprioritize BDTX-4933 and seek potential partners Anticipated cost savings expected to extend cash runway into Q2 2026 CAMBRIDGE, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, announced today a corporate restructuring to focus resources on advancing lead program BDTX-1535 into pivotal development, and to extend the Company's expected cash runway into Q2 2026. BDTX-1535 has demonstrated robust Phase 2 clinical activity acros

BDTX-1535 dose of 200 mg daily selected for pivotal development; favorable tolerability profile and no new safety signals observed Preliminary ORR of 42% in 19 patients at 200 mg with on-target resistance EGFR mutations Encouraging durability with DOR of approximately 8 months or more for first 3 patients with a PR; 14 of 19 patients remain on treatment Regulatory feedback on registration path anticipated in Q1 2025 Initial results of BDTX-1535 in first-line NSCLC patients with non-classical EGFR mutations expected Q1 2025 CAMBRIDGE, Mass., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a clinical-stage oncology company developing MasterKey therapie

Webcast to be held Monday, September 23, at 8:00 a.m. ET CAMBRIDGE, Mass., Sept. 22, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, will host a webcast to disclose initial phase 2 clinical trial results for BDTX-1535 in patients with recurrent EGFRm NSCLC on Monday, September 23, 2024, at 8:00am ET. Webcast information The webcast can be accessed under "Events and Presentations" on the Investors section of the Black Diamond website at www.blackdiamondtherapeutics.com. A replay of the webcast will be available following the comple

Treatment data were analyzed from 3,276 cases of patients with newly diagnosed EGFR mutant NSCLC from Guardant Health Analyses of patients with non-classical EGFR mutations reveal that the majority receive frontline chemotherapy and the remainder are treated with osimertinib or afatinib Short time to treatment discontinuation ranging from four to eight months demonstrates clear unmet need for patients with non-classical EGFR mutant NSCLC CAMBRIDGE, Mass., Sept. 14, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today prese

BDTX-1535, an epidermal growth factor receptor (EGFR) MasterKey inhibitor, demonstrates clinical proof of activity for MasterKey mutation-targeting approach based on radiographic tumor responses and circulating tumor DNA changes in NSCLC patients with acquired resistance and intrinsic driver EGFR mutations Confirmed radiographic partial response by RECIST 1.1 achieved across predicted therapeutic doses in 5 of 12 NSCLC patients in subgroup with measurable disease, who underwent post baseline tumor assessment by RECIST1.1; one additional patient demonstrated unconfirmed PR awaiting confirmation, while the remaining six patients had stable diseaseExpansion cohorts expected to commence i

4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)

4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)

4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)

4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)

4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)

4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)

4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)

4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)

4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)

4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)

4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)

Raymond James initiated coverage of Black Diamond Therapeutics with a rating of Outperform and set a new price target of $20.00

Piper Sandler initiated coverage of Black Diamond Therapeutics with a rating of Overweight

Stifel upgraded Black Diamond Therapeutics from Hold to Buy and set a new price target of $10.00 from $2.00 previously

H.C. Wainwright upgraded Black Diamond Therapeutics from Neutral to Buy and set a new price target of $11.00

Wedbush upgraded Black Diamond Therapeutics from Neutral to Outperform and set a new price target of $10.00

Wedbush downgraded Black Diamond Therapeutics from Outperform to Neutral

H.C. Wainwright downgraded Black Diamond Therapeutics from Buy to Neutral

Stifel initiated coverage of Black Diamond Therapeutic with a rating of Hold and set a new price target of $10.00

SC 13G/A - Black Diamond Therapeutics, Inc. (0001701541) (Subject)

SC 13G - Black Diamond Therapeutics, Inc. (0001701541) (Subject)

SC 13D/A - Black Diamond Therapeutics, Inc. (0001701541) (Subject)

SC 13G/A - Black Diamond Therapeutics, Inc. (0001701541) (Subject)

SC 13D/A - Black Diamond Therapeutics, Inc. (0001701541) (Subject)

SC 13D/A - Black Diamond Therapeutics, Inc. (0001701541) (Subject)

SC 13G/A - Black Diamond Therapeutics, Inc. (0001701541) (Subject)

SC 13G - Black Diamond Therapeutics, Inc. (0001701541) (Subject)

SC 13G/A - Black Diamond Therapeutics, Inc. (0001701541) (Subject)

SC 13D/A - Black Diamond Therapeutics, Inc. (0001701541) (Subject)

DEFA14A - Black Diamond Therapeutics, Inc. (0001701541) (Filer)

DEF 14A - Black Diamond Therapeutics, Inc. (0001701541) (Filer)

SCHEDULE 13G/A - Black Diamond Therapeutics, Inc. (0001701541) (Subject)

8-K - Black Diamond Therapeutics, Inc. (0001701541) (Filer)

S-8 - Black Diamond Therapeutics, Inc. (0001701541) (Filer)

10-K - Black Diamond Therapeutics, Inc. (0001701541) (Filer)

8-K - Black Diamond Therapeutics, Inc. (0001701541) (Filer)

SCHEDULE 13G/A - Black Diamond Therapeutics, Inc. (0001701541) (Subject)

10-Q - Black Diamond Therapeutics, Inc. (0001701541) (Filer)

8-K - Black Diamond Therapeutics, Inc. (0001701541) (Filer)

SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic organ diseases, today announced the appointment of David M. Epstein, Ph.D., to Gyre's Board of Directors (the "Board"), effective August 6, 2024. Dr. Epstein will serve as a member of the Audit Committee of the Board and as member of the Compensation Committee of the Board. "We are thrilled to welcome David to the Gyre Board," said Han Ying, Ph.D., Chief Executive Officer of Gyre Therapeutics. "His extensive global experience in biotech companies across the U.S. and Asia will be

CAMBRIDGE, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancers, today announced that industry veterans Shannon Campbell and Prakash Raman, Ph.D., have been appointed to the Company's Board of Directors. The Company also announced that Wendy Dixon, Ph.D., and Alex Mayweg, Ph.D., have stepped down as members of its Board of Directors. These changes became effective as of April 10, 2024. "On behalf of the board, I am excited to welcome Shannon and Prakash, both seasoned executives who bring deep and highly relevant oncolog

Presented BDTX-1535 Phase 1 dose escalation data showing durable anti-tumor activity and favorable safety profile in NSCLC patients across heterogeneous EGFR mutations at the October 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsBDTX-1535 NSCLC expansion cohorts enrolling, initial data expected in 2024BDTX-1535 Phase 1 dose escalation data in GBM expected later this yearDosed first patient in a Phase 1 trial of BDTX-4933, a brain-penetrant RAF inhibitor targeting KRAS, NRAS and BRAF alterations in solid tumors Cash, cash equivalents, and investments of $144.3 million as of September 30, 2023, expected to be sufficient to fund operations into the fir

Presented new data at the 34th EORTC-NCI-AACR Symposium highlighting robust preclinical anti-tumor activity of BDTX-1535 and BDTX-4933 across multiple families of oncogenic mutations while sparing wild type; both MasterKey therapies demonstrate key attributes of next generation small molecule inhibitorsOn track to provide a clinical update on BDTX-1535 in 2023 and to file an IND for BDTX-4933 in the first half of 2023Strengthened clinical development leadership with appointment of Melanie Morrison as Senior Vice President, Development Operations, who brings over two decades of experience in oncology drug developmentCash, cash equivalents and investments of approximately $144.2 million as of

Strengthened leadership team with appointment of Sergey Yurasov, M.D., Ph.D., as Chief Medical OfficerAdvanced MasterKey therapy pipeline with first patient dosed in Phase 1 global study of BDTX-1535, and continued IND-enabling studies of BDTX-4933Cash, cash equivalents and investments of approximately $160.9 million as of June 30, 2022; expected to be sufficient to fund operations into the third quarter of 2024 CAMBRIDGE, Mass. and NEW YORK, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today reported financial results for the second quarter ended Jun

CAMBRIDGE, Mass. and NEW YORK, April 07, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced the appointment of Wendy L. Dixon, Ph.D., to its Board of directors. Additionally, Brad Bolzon, Ph.D., Chairman and Managing Director of Versant Ventures and a member of Black Diamond's Board of Directors since 2017, has resigned from the Board. "Brad's contributions to Black Diamond over the last five years have been invaluable. He has supported the company from its founding through many stages of our development including our path to becoming a public comp

CAMBRIDGE, Mass. and NEW YORK, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced the appointment of Elizabeth Montgomery as its first Chief People Officer. Ms. Montgomery brings almost 20 years of global human resources leadership experience in the life sciences industry. In the newly created role, Ms. Montgomery will be a key member of the executive leadership team and have responsibility for the development and execution of Black Diamond's people and talent strategy. "We are thrilled to welcome Elizabeth to the Black Diamond executive tea

Initial Phase 1 clinical PK, safety, and preliminary efficacy data for BDTX-189 presented at ASCO Annual Meeting; on track to initiate Phase 2 portion of MasterKey-01 study in second half of 2021Pre-clinical data for BDTX-1535 presented at AACR Annual Meeting; program on track to enter the clinic in 2022Early-stage pipeline programs targeting BRAF and FGFR remain on track for IND filing in 2022Biotech industry veteran Mark Velleca, M.D., Ph.D., appointed to Board of DirectorsCash, cash equivalents, and investments of $263.5 million as of June 30, 2021, expected to be sufficient to fund operations into 2023 CAMBRIDGE, Mass. and NEW YORK, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Black Diamond Ther

CAMBRIDGE, Mass. and NEW YORK, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, MasterKey therapies, today announced the appointment of Mark A. Velleca, M.D., Ph.D. to its Board of Directors. Dr. Velleca brings over 20 years of leadership experience in the biotechnology industry, particularly in the field of oncology, most recently serving as Chief Executive Officer of G1 Therapeutics. "I am delighted to welcome Mark to the Black Diamond Board of Directors," said Robert A. Ingram, Chairman of the Board of Directors of Black Diamond Therapeutics. "Mark brings s

CAMBRIDGE, Mass. and NEW YORK, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced the appointment of Dr. Kapil Dhingra to its Board of Directors. Dr. Dhingra has more than 30 years’ experience in oncology clinical research and drug development, including as Vice President, Head of the Oncology Disease Biology Leadership Team and Head of Oncology Clinical Development at Hoffmann-La Roche (“Roche”). He has served as a clinical and strategic advisor to Black Diamond since 2017. “I am delighted to welcome Kapil to the Black